These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 29121759)

  • 21. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
    Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.
    Molife C; Frech-Tamas F; DeKoven M; Effron MB; Karkare S; Zhu Y; Larmore C; Lu J; McCollam P; Marrett E; Vetrovec GW
    J Med Econ; 2015; 18(11):898-908. PubMed ID: 26086414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Aytekin A; Ndrepepa G; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Lahu S; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Valina C; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
    Circulation; 2020 Dec; 142(24):2329-2337. PubMed ID: 33115278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
    Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
    Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
    Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
    Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
    Tscharre M; Egger F; Machata M; Rohla M; Michael N; Neumayr M; Zweiker R; Hajos J; Adlbrecht C; Suppan M; Helmreich W; Eber B; Huber K; Weiss TW
    PLoS One; 2017; 12(6):e0179349. PubMed ID: 28632784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Malik AH; Gupta R; Chakraborty S; Mahajan P; Bandyopadhyay D; Yandrapalli S; Zaid S; Sreenivasan J; Chaturvedi A; Mehta SS; Vyas AV; Patel NC; Combs WG; Ahmad H
    Cardiovasc Revasc Med; 2022 Aug; 41():115-121. PubMed ID: 35033458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
    Faggioni M; Baber U; Chandrasekhar J; Sartori S; Claessen BE; Rao SV; Vogel B; Effron MB; Poddar K; Farhan S; Kini A; Weintraub W; Toma C; Sorrentino S; Weiss S; Snyder C; Muhlestein JB; Kapadia S; Keller S; Strauss C; Aquino M; Baker B; Defranco A; Pocock S; Henry T; Mehran R
    Int J Cardiol; 2019 Jan; 275():31-35. PubMed ID: 30391067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
    Bagai A; Peterson ED; Honeycutt E; Effron MB; Cohen DJ; Goodman SG; Anstrom KJ; Gupta A; Messenger JC; Wang TY
    Eur Heart J Acute Cardiovasc Care; 2015 Dec; 4(6):499-508. PubMed ID: 25515725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prasugrel in the treatment of acute coronary syndrome.
    Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V
    Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of major adverse cardiovascular events of
    Biswas M; Kali MSK; Biswas TK; Ibrahim B
    Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Efficacy and Safety of Oral P2Y
    Navarese EP; Khan SU; Kołodziejczak M; Kubica J; Buccheri S; Cannon CP; Gurbel PA; De Servi S; Budaj A; Bartorelli A; Trabattoni D; Ohman EM; Wallentin L; Roe MT; James S
    Circulation; 2020 Jul; 142(2):150-160. PubMed ID: 32468837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.
    Hong J; Turgeon RD; Pearson GJ
    Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764
    [No Abstract]   [Full Text] [Related]  

  • 39. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.
    Alexopoulos D; Vogiatzi C; Stavrou K; Vlassopoulou N; Perperis A; Pentara I; Xanthopoulou I
    Cardiovasc Diabetol; 2015 May; 14():68. PubMed ID: 26025572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.